NCT02339805View on ClinicalTrials.gov

Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2016

Conditions
Non Hodgkin Lymphoma
Interventions
OTHER

next generation sequencing

DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.

DEVICE

Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)

tumor Assessment tool during the study

Trial Locations (1)

76038

Centre Henri Becquerel, Rouen

All Listed Sponsors
collaborator

U918 ( Inserm unit)

UNKNOWN

lead

Centre Henri Becquerel

OTHER

NCT02339805 - Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS | Biotech Hunter | Biotech Hunter